Bio-Techne Corp
TECH50.520USD
-1.010-1.96%
Fechamento 06/13, 16:00（ET）Cotações atrasadas em 15 min
7.92BValor de mercado
50.09P/L TTM
Mais detalhes de Bio-Techne Corp Empresa
Bio-Techne Corporation is a global life sciences company providing tools and bioactive reagents for the research and clinical diagnostic communities. The Company's products assist scientific investigations into biological processes and the nature and progress of specific diseases. The Company, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex Bioreactors. Its segments include Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-based molecular diagnostic assays, and tissue biopsy analysis.
Informações da empresa
Código da empresaTECH
Nome da EmpresaBio-Techne Corp
Data de listagemFeb 09, 1989
Fundado em1981
CEOMr. Kim Kelderman
Número de funcionários3100
Tipo de títulosOrdinary Share
Fim do ano fiscalFeb 09
Endereço614 Mckinley Pl N E
CidadeMINNEAPOLIS
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal55413
Telefone16123792956
Sitehttps://www.bio-techne.com/
Código da empresaTECH
Data de listagemFeb 09, 1989
Fundado em1981
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. John L. Higgins
Mr. John L. Higgins
Independent Director
Independent Director
60.20K
+24.90%
Mr. Robert V. (Bob) Baumgartner, CPA
Mr. Robert V. (Bob) Baumgartner, CPA
Independent Chairman of the Board
Independent Chairman of the Board
44.86K
+3.37%
Dr. Roeland Nusse, Ph.D.
Dr. Roeland Nusse, Ph.D.
Independent Director
Independent Director
44.56K
+3.39%
Mr. Kim Kelderman
Mr. Kim Kelderman
President, Chief Executive Officer, Chief Operating Officer, Director
President, Chief Executive Officer, Chief Operating Officer, Director
37.51K
--
Dr. Joseph D. (Joe) Keegan, Ph.D.
Dr. Joseph D. (Joe) Keegan, Ph.D.
Independent Director
Independent Director
13.77K
+11.88%
Dr. Rupert J. Vessey, Ph.D.
Dr. Rupert J. Vessey, Ph.D.
Independent Director
Independent Director
9.35K
+18.54%
Ms. Julie L. Bushman
Ms. Julie L. Bushman
Independent Director
Independent Director
7.13K
+25.77%
Mr. Shane Bohnen
Mr. Shane Bohnen
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
3.19K
+90.01%
Dr. Matthew F. Mcmanus
Dr. Matthew F. Mcmanus
President - Diagnostics and Genomics Segment
President - Diagnostics and Genomics Segment
2.98K
--
Dr. Judith V. Klimovsky, M.D.
Dr. Judith V. Klimovsky, M.D.
Independent Director
Independent Director
2.14K
+215.00%
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. John L. Higgins
Mr. John L. Higgins
Independent Director
Independent Director
60.20K
+24.90%
Mr. Robert V. (Bob) Baumgartner, CPA
Mr. Robert V. (Bob) Baumgartner, CPA
Independent Chairman of the Board
Independent Chairman of the Board
44.86K
+3.37%
Dr. Roeland Nusse, Ph.D.
Dr. Roeland Nusse, Ph.D.
Independent Director
Independent Director
44.56K
+3.39%
Mr. Kim Kelderman
Mr. Kim Kelderman
President, Chief Executive Officer, Chief Operating Officer, Director
President, Chief Executive Officer, Chief Operating Officer, Director
37.51K
--
Dr. Joseph D. (Joe) Keegan, Ph.D.
Dr. Joseph D. (Joe) Keegan, Ph.D.
Independent Director
Independent Director
13.77K
+11.88%
Dr. Rupert J. Vessey, Ph.D.
Dr. Rupert J. Vessey, Ph.D.
Independent Director
Independent Director
9.35K
+18.54%
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de abr
Moeda: USDAtualizado em: dom, 6 de abr
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2021
FY2020
FY2019
Por EmpresaUSD
Nome
Receita
Proporção
Consumables
230.72M
77.67%
Instruments
30.87M
10.39%
Service
27.35M
9.21%
Royalty
8.10M
2.73%
Por RegiãoUSD
Nome
Receita
Proporção
United States
159.91M
53.83%
EMEA, excluding U.K
70.39M
23.70%
Greater China
24.75M
8.33%
APAC, excluding Greater China
19.01M
6.40%
United Kingdom
13.24M
4.46%
Rest of World
9.73M
3.27%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Consumables
230.72M
77.67%
Instruments
30.87M
10.39%
Service
27.35M
9.21%
Royalty
8.10M
2.73%
Distribuição de ações
Atualizado em: qua, 14 de mai
Atualizado em: qua, 14 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
11.77%
T. Rowe Price Associates, Inc.
7.11%
BlackRock Institutional Trust Company, N.A.
5.94%
State Street Global Advisors (US)
4.17%
Select Equity Group, L.P.
3.42%
Other
67.59%
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
11.77%
T. Rowe Price Associates, Inc.
7.11%
BlackRock Institutional Trust Company, N.A.
5.94%
State Street Global Advisors (US)
4.17%
Select Equity Group, L.P.
3.42%
Other
67.59%
Tipos de investidores
Investidores
Proporção
Investment Advisor/Hedge Fund
48.59%
Investment Advisor
46.42%
Hedge Fund
2.66%
Research Firm
2.30%
Bank and Trust
2.19%
Pension Fund
1.94%
Sovereign Wealth Fund
1.33%
Individual Investor
1.06%
Insurance Company
0.25%
Participação acionária institucional
Atualizado em: seg, 20 de jan
Atualizado em: seg, 20 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q1
1219
163.12M
103.18%
-2.03M
2024Q4
1233
162.21M
102.61%
-6.39M
2024Q3
1205
159.40M
100.49%
-10.21M
2024Q2
1207
160.52M
101.86%
-12.24M
2024Q1
1216
162.56M
103.40%
-7.57M
2023Q4
1229
159.70M
100.98%
-3.97M
2023Q3
1217
156.41M
98.84%
-7.93M
2023Q2
1213
155.36M
98.68%
-4.04M
2023Q1
1206
153.08M
97.33%
-5.18M
2022Q4
1190
153.16M
97.57%
-6.72M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
The Vanguard Group, Inc.
18.52M
11.72%
+275.81K
+1.51%
Dec 31, 2024
T. Rowe Price Associates, Inc.
10.43M
6.6%
+1.23M
+13.34%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
9.25M
5.85%
+4.60K
+0.05%
Dec 31, 2024
State Street Global Advisors (US)
6.47M
4.09%
+76.69K
+1.20%
Dec 31, 2024
Select Equity Group, L.P.
2.34M
1.48%
+495.40K
+26.92%
Dec 31, 2024
Geode Capital Management, L.L.C.
4.00M
2.53%
+98.66K
+2.53%
Dec 31, 2024
Atlanta Capital Management Company, L.L.C.
2.95M
1.87%
-40.17K
-1.34%
Dec 31, 2024
Baron Capital Management, Inc.
4.14M
2.62%
-308.56K
-6.94%
Dec 31, 2024
Neuberger Berman, LLC
3.58M
2.27%
+65.69K
+1.87%
Dec 31, 2024
MFS Investment Management
2.52M
1.59%
-59.23K
-2.30%
Dec 31, 2024
Ver Mais
ETFs Relacionados
Atualizado em: sex, 6 de jun
Atualizado em: sex, 6 de jun
Nome
Proporção
Global X Genomics & Biotechnology ETF
3.58%
Invesco Biotechnology & Genome ETF
2.18%
VanEck Biotech ETF
1.59%
Thrivent Small-Mid Cap ESG ETF
1.53%
Hilton Small-MidCap Opportunity ETF
1.5%
Nuveen ESG Mid-Cap Growth ETF
1.37%
Invesco S&P 500 Equal Weight Health Care ETF
1.36%
WisdomTree BioRevolution Fund
1.2%
Tema Monopolies and Oligopolies ETF
1.15%
iShares Health Innovation Active ETF
1.14%
Ver Mais
Global X Genomics & Biotechnology ETF
Proporção3.58%
Invesco Biotechnology & Genome ETF
Proporção2.18%
VanEck Biotech ETF
Proporção1.59%
Thrivent Small-Mid Cap ESG ETF
Proporção1.53%
Hilton Small-MidCap Opportunity ETF
Proporção1.5%
Nuveen ESG Mid-Cap Growth ETF
Proporção1.37%
Invesco S&P 500 Equal Weight Health Care ETF
Proporção1.36%
WisdomTree BioRevolution Fund
Proporção1.2%
Tema Monopolies and Oligopolies ETF
Proporção1.15%
iShares Health Innovation Active ETF
Proporção1.14%
Dividendo
Um total de
249.41M
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Feb 05, 2025
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Feb 28, 2025 going ex on Feb 14, 2025
Feb 17, 2025
Feb 28, 2025
Feb 14, 2025
Oct 30, 2024
TECH.NB Final Cash Dividend of gross USD 0.08 paid on Nov 22, 2024 going ex on Nov 08, 2024
Nov 11, 2024
Nov 22, 2024
Nov 08, 2024
Aug 07, 2024
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Aug 30, 2024 going ex on Aug 19, 2024
Aug 19, 2024
Aug 30, 2024
Aug 19, 2024
May 01, 2024
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on May 24, 2024 going ex on May 10, 2024
May 13, 2024
May 24, 2024
May 10, 2024
Feb 01, 2024
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Feb 26, 2024 going ex on Feb 09, 2024
Feb 12, 2024
Feb 26, 2024
Feb 09, 2024
Oct 31, 2023
TECH.NB Final Cash Dividend of gross USD 0.08 paid on Nov 24, 2023 going ex on Nov 09, 2023
Nov 10, 2023
Nov 24, 2023
Nov 09, 2023
Aug 08, 2023
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Sep 01, 2023 going ex on Aug 17, 2023
Aug 18, 2023
Sep 01, 2023
Aug 17, 2023
May 03, 2023
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on May 26, 2023 going ex on May 12, 2023
May 15, 2023
May 26, 2023
May 12, 2023
Feb 02, 2023
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Feb 27, 2023 going ex on Feb 10, 2023
Feb 13, 2023
Feb 27, 2023
Feb 10, 2023
Nov 01, 2022
TECH.NB Final Cash Dividend of gross USD 0.32 paid on Nov 28, 2022 going ex on Nov 10, 2022
Nov 14, 2022
Nov 28, 2022
Nov 10, 2022
Ver Mais
Desdobramento de ações
Data
Tipo
Proporção
Nov 01, 2022
Split
1>4
Data
Tipo
Proporção
Nov 01, 2022
Split
1>4
